kabutan

3-D Matrix,Ltd.(7777) Summary

7777
TSE Growth
3-D Matrix,Ltd.
567
JPY
-150
(-20.92%)
L-Down
Mar 13, 3:30 pm JST
3.55
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
518
Mar 14, 1:07 am JST
Summary Chart Historical News Financial Result
PER
68.9
PBR
15.0
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:18 am
637 JPY 4.00 USD
Previous Close Mar 12
717 JPY 4.51 USD
High Mar 13, 9:19 am
656 JPY 4.12 USD
Low Mar 13, 9:42 am
567 JPY 3.55 USD
Volume
23,134,000
Trading Value
0.01T JPY 0.09B USD
VWAP
589.17 JPY 3.7 USD
Minimum Trading Value
56,700 JPY 355 USD
Market Cap
0.07T JPY 0.44B USD
Number of Trades
12,607
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
1,960
1-Year High Sep 16, 2025
16,543
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 13,154,600
Feb 27, 2026 8,200 12,169,500 1484.09
Feb 20, 2026 2,300 13,422,800 5836.00
Feb 13, 2026 0 14,220,000
Feb 6, 2026 600 15,322,200 25537.00
Company Profile
3-D Matrix, Ltd. is a bioventure company that develops medical products by applying peptide technology. The company operates both domestically and internationally.
Sector
Precision Instruments
3-D Matrix, Ltd. conducts research and development, manufacturing, and sales of medical devices and pharmaceuticals based on self-assembling peptide technology, for which it has obtained an exclusive license from MIT. The company's main development pipeline includes absorbable local hemostatic agents for surgical applications, mucosal lifting agents, post-bleeding prevention materials, adhesion prevention materials, wound healing materials for tissue regeneration, alveolar bone reconstruction materials, and drug delivery systems (DDS) for nucleic acid therapeutics. 3-D Matrix has established direct sales systems in the United States, Japan, and Australia, while also conducting sales through partner companies in some regions.